The short version of purity certificate fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-19 and is reviewed periodically as new material appears.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or powder |
| Solubility class | Freely soluble in water | Aqueous buffers also used |
| Typical storage temperature | About -20 degrees Celsius | Dry, sealed and protected from light |
| Typical analytical method | Reversed-phase HPLC or LC-MS/MS | Used for purity, identity and quantification |
| Common synonyms | Thymosin beta-4 fragment | Also listed under fragment-based descriptions |
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
== Semantics of changing care: why "flexible" is replacing "intensive" therapy == Over the last two decades, the evidence that better glycemic control (i.e., keeping blood glucose and HbA1c levels as close to normal as possible) reduces the rates of many complications of diabetes has become overwhelming. As a result, diabetes specialists have expended increasing effort to help most people with diabetes achieve blood glucose levels as close to normal as achievable. It takes about the same amount of effort to achieve good glycemic control with a traditional two or three injection regimen as it does with flexible therapy: frequent glucose monitoring, attention to timing and amounts of meals. Many diabetes specialists no longer think of flexible insulin therapy as "intensive" or "special" treatment for a select group of patients but simply as standard care for most patients with type 1 diabetes.
== B == B-cell lymphoma – B cells – B lymphocytes (B cells) – bactericidal – bacteriostatic – bacterium – baculovirus – baseline – basophil – bDNA test – beta-2 microglobulin (β2M) – bilirubin – bioavailability – biological response modifiers (BRMs) – biopsy – biotechnology – blinded study – blips – blood–brain barrier – body fat redistribution (BFR) syndrome – body fluids – bone marrow – bone marrow suppression – booster – branched DNA assay – breakthrough infection – Broadway Cares/Equity Fights AIDS – bronchoscopy – budding – buffalo hump – bugchasing and giftgiving – Burkitt's lymphoma
CNS excitation: nervousness, agitation, anxiety, apprehension, tingling around the mouth (circumoral paraesthesia), headache, hyperesthesia, tremor, dizziness, pupillary changes, psychosis, euphoria, hallucinations, and seizures CNS depression with heavier exposure: drowsiness, lethargy, slurred speech, hypoesthesia, confusion, disorientation, loss of consciousness, respiratory depression, and apnoea. Cardiovascular: hypotension, bradycardia, arrhythmias, flushing, venous insufficiency, increased defibrillator threshold, edema, and/or cardiac arrest – some of which may be due to hypoxemia secondary to respiratory depression. Respiratory: bronchospasm, dyspnea, respiratory depression or arrest Gastrointestinal: metallic taste, nausea, vomiting, agita, and diarrhea Ears: tinnitus Eyes: local burning, conjunctival hyperemia, corneal epithelial changes/ulceration, diplopia, visual changes (opacification) Skin: itching, depigmentation, rash, urticaria, edema, angioedema, bruising, inflammation of the vein at the injection site, irritation of the skin when applied topically Blood: methemoglobinemia Allergy ADRs associated with the use of intravenous lidocaine are similar to the toxic effects of systemic exposure above. These are dose-related and more frequent at high infusion rates (≥3 mg/min). Common ADRs include headache, dizziness, drowsiness, confusion, visual disturbances, tinnitus, tremor, and/or paraesthesia.
Sources: en.wikipedia.org
Only 10 to 15% of tumours are suitable for surgical resection. As of 2018, when chemotherapy is given the FOLFIRINOX regimen containing fluorouracil, irinotecan, oxaliplatin and leucovorin has been shown to extend survival beyond traditional gemcitabine regimens. For the most part, treatment is palliative, focusing on the management of symptoms that develop. This may include management of itch, a choledochojejunostomy, or the insertion of stents with ERCP to facilitate the drainage of bile, and medications to help control pain. In the United States, pancreatic cancer is the fourth most common cause of death due to cancer. The disease occurs more often in the developed world, which had 68% of new cases in 2012. Pancreatic adenocarcinoma typically has poor outcomes, with the average percentage alive for at least one and five years after diagnosis being 25% and 5% respectively. In localized disease where the cancer is small (< 2 cm) the number alive at five years is approximately 20%. There are several types of pancreatic cancer, involving both the endocrine and exocrine tissue. The many types of pancreatic endocrine tumors are all uncommon or rare, and have varied outlooks. However, the incidence of these cancers has been rising sharply; it is not clear to what extent this reflects increased detection, especially through medical imaging, of tumors that would be very slow to develop. Insulinomas (largely benign) and gastrinomas are the most common types.
(WINNER) The contestant won the whole competition. ‡ The contestant won the Pre-Heat challenge. (WIN) The contestant won the Main Heat challenge. (HIGH) The contestant had one of the best dishes for that week. (IN) The contestant performed well enough to move on to the next week. (LOW) The contestant had one of the bottom dishes for that week, but was not eliminated. (OUT) The contestant was eliminated for worst dish.
Gordon Biersch combines German-style beer and its made-from-scratch cuisine. Featuring German lagers brewed according to the German Purity Law of 1516 (Reinheitsgebot), Gordon Biersch has won numerous gold medals at both the Great American Beer Festival and World Beer Cup. Gordon Biersch offers a made-from-scratch American menu with international flavors. The first Gordon Biersch opened in Palo Alto, California. The company was acquired by Big River Brewing Company in 1999 and later renamed Gordon Biersch Brewery Restaurant Group, Inc. The company reported six locations in Taiwan.
In archaea such as Thermoplasma acidophilum, all the α and all the β subunits are identical, whereas eukaryotic proteasomes such as those in yeast contain seven distinct types of each subunit. In mammals, the β1, β2, and β5 subunits are catalytic; although they share a common mechanism, they have three distinct substrate specificities considered chymotrypsin-like, trypsin-like, and peptidyl-glutamyl peptide-hydrolyzing (PHGH). Alternative β forms denoted β1i, β2i, and β5i can be expressed in hematopoietic cells in response to exposure to pro-inflammatory signals such as cytokines, in particular, interferon gamma. The proteasome assembled with these alternative subunits is known as the immunoproteasome, whose substrate specificity is altered relative to the normal proteasome. Recently an alternative proteasome was identified in human cells that lack the α3 core subunit. These proteasomes (known as the α4-α4 proteasomes) instead form 20S core particles containing an additional α4 subunit in place of the missing α3 subunit. These alternative 'α4-α4' proteasomes have been known previously to exist in yeast. Although the precise function of these proteasome isoforms is still largely unknown, cells expressing these proteasomes show enhanced resistance to toxicity induced by metallic ions such as cadmium. The peptides that are formed by the 20S core have recently been shown to act as important metabolites for both programmed cell death and for immunity.
Sources: en.wikipedia.org
6 September – Researchers at the University of Edinburgh report a theoretical framework using optimal control to enable ultrafast, highly energy-efficient switching of magnetic memory. Computer simulations suggest that optimised magnetic-field pulses could reduce switching energy by orders of magnitude compared with existing memory technologies, bringing it substantially closer to the Landauer limit, the theoretical minimum energy required to process information. 8 September – OpenAI reports an AI-generated solution to the Navier–Stokes problem, one of the seven Millennium Prize Problems. The proposed proof shows that equations describing fluid motion can produce infinite speeds under certain conditions, revealing limits to their ability to represent real fluids. 15 September – A review published in Psychological Medicine finds that reading for pleasure is associated with better brain health, cognition and mental well-being across the lifespan, including improved attention and memory in children and a lower risk of cognitive decline and dementia in older adults. Neuroimaging studies also associate reading with structural and functional differences in brain regions involved in executive control, emotional regulation and social cognition. 17 September – A genomic study of South American tiger cats identifies Leopardus tilcayo, a small wild cat from Bolivia's Yungas, as a distinct species. The researchers describe it as the first entirely novel living felid species identified in more than a century.
If, in addition, the rate of photoionization is greater than the rate of consumption of intermediates, then each selected state is converted to one electron plus one positive ion, so that the RIS process is saturated. A usually efficient way to produce free atoms of an element in the ground state is to atomize the elements by ion sputtering or thermal vaporization of the element from a laser matrix under vacuum conditions or at environments with pressures significantly less than normal atmospheric pressure. The resulting plume of secondary atoms is then channeled through the path of multiple tuned laser beams which are capable of exciting consecutive electronic transitions in the specified element. Light from these tuned lasers promotes the desired atoms above their ionization potentials whereas interfering atoms from other elements are hardly ionized since they are generally transparent to the laser beam. This process produces photoions which are extracted and directed towards an analytical facility such as a magnetic sector to be counted. This approach is extremely sensitive to atoms of the specified element so that the ionization efficiency is almost 100% and also elementally selective, due to the highly unlikely chance that other species will be resonantly ionized. To achieve high ionization efficiencies, monochromatic lasers with high instantaneous spectral power are used. Typical lasers being used include continuous-wave lasers with extremely high spectral purity and pulsed lasers for analyses involving limited atoms.
ago. A more correct treatment would require the use of delay differential equations. Latent period is the transition time between contagion event and disease manifestation. In cases of diseases with varying latent periods, the basic reproduction number can be calculated as the sum of the reproduction numbers for each transition time into the disease. An example of this is tuberculosis (TB). Blower and coauthors calculated from a simple model of TB the following reproduction number:
12 September – Bill Wilson, lawyer and judge, judge of the Court of Appeal (2007–2008) and Supreme Court (2008–2010), King's Counsel (since 1996) (born 1946). 13 September – Stan Simpson, wool scientist (WRONZ) and science administrator, director of WRONZ (1978–1992) (born 1933). 14 September – Barry Roberts, cricketer (Northern Districts) (born 1946). 16 September Judy Tinnock, tennis player, Wimbledon mixed doubles semi-finalist (1954) (born 1931). Jack Williams, cricketer (Canterbury) (born 1931). 17 September Tenick Dennison, paediatrician, conservationist and ornithologist (born 1927). Jim Easton, oldest living man in New Zealand (108 years, 279 days), oldest living Australian World War II veteran (born 1916). Dame Joan Metge, social anthropologist (University of Auckland, Victoria University of Wellington), Te Rangi Hiroa Medal (1997) (born 1930). 20 September – Tui Te Rupe, Paralympic marathon runner (1988) (born 1943). 21 September Stu Freebairn, rugby union player (Manawatu, national team) (born 1932). William E. Shepard, religious studies academic (University of Canterbury) (born 1933). 22 September Ian Farquhar, maritime historian, businessman and local politician, chair of the Otago Harbour Board (1980–1983) (born 1931). Grant Hawke, Māori leader (Ngāti Whātua Ōrākei) (born 1944). 23 September Bruce Morrison, cricketer (Wellington, national team) (born 1933). Sir Tumu Te Heuheu, Māori leader, paramount chief of Ngāti Tūwharetoa (since 1997) (born 1941). 25 September Glynn Jones, physicist (University of Canterbury) (born 1936).
Chiral analysis refers to the quantification of component enantiomers of racemic drug substances or pharmaceutical compounds. Other synonyms commonly used include enantiomer analysis, enantiomeric analysis, and enantioselective analysis. Chiral analysis includes all analytical procedures focused on the characterization of the properties of chiral drugs. Chiral analysis is usually performed with chiral separation methods where the enantiomers are separated on an analytical scale and simultaneously assayed for each enantiomer. Many compounds of biological and pharmacological interest are chiral. Pharmacodynamic, pharmacokinetic, and toxicological properties of the enantiomers of racemic chiral drugs has expanded significantly and become a key issue for both the pharmaceutical industry and regulatory agencies. Typically one of the enantiomers is more active pharmacologically (eutomer). In several cases, unwanted side effects or even toxic effects may occur with the inactive enantiomer (distomer). Even if the side effects are not that serious, the inactive enantiomer has to be metabolized, this puts an unnecessary burden on the already stressed out system of the patient. Large differences in activity between enantiomers reveal the need to accurate assessment of enantiomeric purity of pharmaceutical, agrochemicals, and other chemical entities like fragrances and flavors become very important.
Sources: en.wikipedia.org
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.
Reported purity reflects the batch tested, the chromatographic method used and whether an independent laboratory performed the work. Values quoted without method detail or a traceable certificate are difficult to compare directly.
Short peptides are rapidly broken down by proteases and appear at low concentrations in urine, so the detection window is narrow. Sensitive extraction combined with tandem mass spectrometry is typically required.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.